The Brown University Child & Adolescent Psychopharmacology Update Template
Write in a clean editor, then format for The Brown University Child & Adolescent Psychopharmacology Update in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the The Brown University Child & Adolescent Psychopharmacology Update format
The Brown University Child & Adolescent Psychopharmacology Update is a peer-reviewed journal published by Wiley, covering Attention Deficit Hyperactivity Disorder, Child and Adolescent Psychosocial and Emotional Development, Pharmaceutical studies and practices.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." The Brown University Child & Adolescent Psychopharmacology Update 12 (3): 45–58.
Formats any DOI in The Brown University Child & Adolescent Psychopharmacology Update style. No sign-up. |
| Publishes research in | Attention Deficit Hyperactivity Disorder Child and Adolescent Psychosocial and Emotional Development Pharmaceutical studies and practices Opioid Use Disorder Treatment Autism Spectrum Disorder Research |
| ISSN | 1527-8395 |
| Citation impact (2-yr) | 0.03 |
| h-index | 8 |
| i10-index | 6 |
| Total citations | 266 |
| Top institutions publishing here | Cancer Research And Biostatistics |
| Journal website | onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in The Brown University Child & Adolescent Psychopharmacology Update per year
Citation impact of The Brown University Child & Adolescent Psychopharmacology Update by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in The Brown University Child & Adolescent Psychopharmacology Update
The prevalence of autism spectrum disorder (ASD) is now one in 54 children based on 2016 data, up from one in 60 in 2014, according to the Autism and Developmental Disabilities Monitoring (ADDM) Network of the federal Centers for Disease Control and Prevention (CDC). The surveillance program estimates ASD prevalence among children aged 8 living…
Last month, the U.S. Food and Drug Administration permitted marketing of the first mobile medical application to help treat substance use disorder (SUD). The Reset application is intended to be used with outpatient therapy to treat alcohol, cocaine, marijuana, and stimulant SUDs. The application is not intended to be used to treat opioid dependence.
Based on prior research on isolation and loneliness, children and adolescents are more likely to have high rates of depression, and, probably, anxiety, even after the enforced isolation resulting from the COVID‐19 pandemic ends, according to a study published in the Journal of the American Academy of Child and Adolescent Psychiatry . The longer enforced…
In August, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV…